Pfizer IP head says that IP protectionism in India is discouraging foreign investment

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Pfizer IP head says that IP protectionism in India is discouraging foreign investment

Pfizer’s chief IP counsel decries India’s “protectionist intellectual property regime” in testimony before the United States Congress, reports the Financial Times

Speaking at a hearing before the House of Representatives on Wednesday, Roy Waldron of Pfizer argued that India’s intellectual property laws favoured local industries at the expense of international companies. He pointed to the recent revocation of his company’s patent for cancer drug sutent as evidence of an increasingly protectionist IP regime. According to Waldron, the situation has worsened and is discouraging international investment in India.

Waldron also criticised India’s likely increasing use of compulsory licences, even though he claims that Pfizer is “more than willing to discuss viable solutions to increase access to quality medicines”.

Waldron’s comments reflect growing concerns about patent rights in India. Last week, the Intellectual Property Appellate Board (IPAB) upheld the country’s first compulsory licence issued for Bayer's sorafenib. In an interview with Managing IP, IPAB Chairperson Prabha Sridevan defended the board’s decision, calling compulsory licensing a “balanced approach” to protecting the interests of rights holders and the general public.

“Compulsory licences are not a denigration of the owner’s rights,” she argued. “The patent rights are intact until the patent is invalidated.”

The Indian government has indicated that more compulsory licences are almost certainly coming. While the sorafenib compulsory licence was issued under section 84 of the Patent Act, which requires an application from a generic manufacturer, the government itself recently initiated proceedings for three more compulsory licences. The Department of Pharmaceuticals, which initiated the proceedings, relied on section 92, which allows the government to issue compulsory licences in the case of “national emergency or in circumstances of extreme urgency”.

more from across site and SHARED ros bottom lb

More from across our site

Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Half-year Talent Tracker data shows Pierson Ferdinand was among the most prolific hirers in the US, while in Europe, there has been a notable UPC swing
Exclusive data reveals in-house counsel want external legal advisers to build better client relationships and add value beyond routine work
Brett Sandford acted for Perplexity AI, which fended off the threat of a preliminary injunction to launch an AI-powered web browser
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
The complaint follows a declaratory ruling issued by the England and Wales High Court last month that said Samsung is entitled to an interim licence
Tobias Hahn explains how the firm's multi-jurisdictional setup enabled it to secure an injunction on behalf of Fujifilm relating to defendant Kodak’s non-UPC activity
Reckitt Benckiser is to divest its Essential Home business, which includes more than 70 brands, to private equity firm Advent International
Litigator Neel Chatterjee, who has joined the firm as a co-leader of the IP team, reveals tech ambitions and expansion plans
A settlement between Philips and Transsion and a loss for AstraZeneca in the UK were also among the top talking points
Gift this article